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4. Introduction 
4.1 Multiple organ failure 
Multiple organ failure (MOF) is an evolving clinical syndrome triggered by various 
stimuli, arising following successful resuscitation from life-threatening conditions. The 
ongoing support contributes to its subsequent course. It is the main cause of morbidity 
and mortality in patients admitted to intensive care units (1). Organ failure, both in 
terms of the number of organs failing and the degree of organ dysfunction, is the 
strongest predictor of death in a critically ill patient. The mortality rate in these patients 
is 20-80%, depending on the number of organs involved. Although the clinical 
manifestations of MOF may vary, the organs involved typically include the lungs, heart, 
kidneys, brain, liver and / or the gut (2). There is widespread agreement that an 
increased inflammatory response, ischemia and septicaemia are important contributing 
factors to the development of MOF (3-12).  
4.2 The ischemic intestine 
The gut is thought to be a “motor” in the development of MOF (13), and splanchnic 
ischemia is associated with high mortality in critically ill patients (14,15). A number of 
clinical studies on critically ill patients have documented inadequate intestinal blood 
flow, oxygen utilization (16,17) and increased hepatosplanchnic inflammation (18). 
Thus there is an increase in intestinal permeability in a variety of acute conditions, like 
burns, sepsis, cardiogenic shock, trauma, and after major operations (13,19-22). 
The pathogenesis behind the intestinal involvement is different in various conditions.
Studies have suggested that in sepsis tissue injury can occur despite adequate tissue 
oxygenation, (so called dysoxia), where increased blood flow does not improve and 
may rather worsen the situation (23). Further research has demonstrated that this 
dysoxia, also affecting the splanchnic region, can be a result of an acquired intrinsic 
derangement in cellular respiration called “cytopathic hypoxia” (24-26). 
In other conditions, blood flow alterations play a more prominent role; 
The splanchnic vascular bed normally holds 30% of total blood volume and receives 25 
% of total cardiac output. Seventy percent of this is distributed to the small and large 
intestine (27). The venous bed and capacitance vessels (postcapillary venules and veins) 
serve as a blood reservoir, and alfa adrenergic sympathetic nervous stimulation is 
capable of rapidly increasing cardiac preload. Hypovolaemic shock states also result in 
a systemic vasoconstriction throughout the body, this response being particularly 
prominent within the mesenteric circulation (28-30). Gut blood flow also varies in the 
intestinal wall; the mean mucosal blood flow is four times higher than mean muscularis 
blood flow (31). Cellular dysfunction and injury are thus explained by a reduced 
cellular oxygen availability resulting from decreased blood flow, oxygen tension or 
haemoglobin concentration. 
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4.3 The ischemic metabolism  
The glycolytic pathway is employed for the breakdown of glucose to provide energy to 
the cells in the form of ATP. Intermediates from this chain of reaction are of interest 
when monitoring the metabolic state of various tissues. 
The initial stages of glucose metabolism – glycolysis, or the Embden-Meyerhof 
pathway, occur in the cytoplasm of cells, also functioning in a low oxygen environment 
as in poorly perfused tissues. One molecule of glucose is converted into 2 molecules of 
pyruvate, generating 2 molecules of ATP and 2 NADH (figure 1) (32). During normal 
aerobic conditions, pyruvate is transported across the mitochondrial membranes into the 
matrix of the mitochondrion, where the second series of reactions (citric acid cycle) 
takes place. Immediately upon entry into the mitochondrion, pyruvate is metabolized to 
the important intermediate acetyl CoA by the enzyme pyruvate dehydrogenase. This 
process requires oxygen, and as a result, pyruvate is oxidized into CO2 and H2O,
producing 36 ATP molecules.  
If blood flow is impaired and oxygen delivery is diminished, pyruvate cannot enter the 
citric acid cycle. The only source of energy then is the ATP produced from glucose in 
the glycolysis. However, glycolysis is dependent upon available NAD+. Thus the pool 
of NAD+ produced normally in the citric acid cycle will rapidly become consumed. 
Under these circumstances, the source of NAD+ is from reduction of pyruvate to 
lactate, resulting in an increase of lactate and anaerobic metabolism. This causes the 
lactate to the pyruvate ratio (LP-ratio) to increase (normal ratio 10/1).  
With intact mitochondrial function, the excess lactate is rapidly metabolized back to 
pyruvate, once oxygen is available.
Figure 1 
Glucose
Glucose-6-P
Pyruvate
Acetyl-CoA
Lactate (2 ATP+2NADH)
CO2+H2O+36 ATP
(2 ATP+NAD+) O2+
Glucose enters the cell and is metabolized to two pyruvate molecules, 2 ATP 
and 2 NADH. In the presence of oxygen, pyruvate enters the citric acid cycle
in the mitochondria, and 36 ATP is produced. If oxygen is lacking, pyruvate is 
reduced to lactate to generate NAD+ for continuation of the glycolytic pathway.
This gives the net sum of 2 ATP. 
Cytosol
Mitochondria
Pyruvate
dehydrogenase
Lactate dehydrogenase
Respiratory
chain
AerobicAnaerobic
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Elevated blood lactate levels in hemodynamic unstable animals (33-37) or patients 
(38,39) are often thought to reflect circulatory shock or hypoxaemia, when O2
consumption becomes dependent upon O2 delivery. As lactate in the blood is 
metabolized in a large part by the liver, liver function and liver blood flow influence 
hepatic lactate clearance. However, other co-factors may co-exist, complicating the 
interpretation of hyperlactataemia.  
In septic shock the reason behind the often observed hyperlactataemia is under debate. 
But at least two situations are usually accompanied by hypoxia-associated 
hyperlactataemia; septic shock with catecholamine-resistant cardiocirculatory failure 
(38), and also initially in septic hypovolaemic patients observed prior to volumetric 
expansion. The latter is illustrated in the study of Rivers et al. (40), in which 
hyperlactataemia is associated with signs of poor oxygen delivery. These two situations 
are, nonetheless, close to low cardiac output states. 
A number of papers have suggested that lactate formation during sepsis is not due to 
hypoxia alone, but rather to metabolic processes with aerobic production of lactate (41). 
This is seen in sepsis where endogenous epinephrine release stimulates sarcolemmal 
Na+ K+ ATPase-coupled lactate production (42). Another factor is the accumulation of 
pyruvate due to accelerated aerobic glycolysis resulting from an increased influx of 
glucose (43). Muscle protein catabolism is also a contributing factor when released 
amino acids are subsequently transformed into pyruvate and thereafter lactate. The 
activity of the enzyme pyruvate dehydrogenase is impaired by tumor necrosis factor in 
septic patients (44), further indicating that this increased lactate should not necessarily 
be taken as proof of oxygen debt, but rather as a sign of lactate dyshomeostasis. 
However, increased lactate is a warning sign and highly predicts outcome in critically ill 
patients (45-47).
4.4 Intestinal barrier dysfunction 
Epithelial dysfunction may be a common final pathway contributing to organ 
dysfunction in sepsis and other forms of critical illness (48). The intestinal epithelium 
acts as a barrier between intestinal content and a) extracellular space b) blood capillaries 
and c) lymph ducts. The gut lumen is separated from the lamina propria by the intestinal 
epithelium, the tight junctions between adjacent cells making the epithelial sheet. The 
tight junction serves as a regulated, semi-permeable barrier that limits the passive 
diffusion of solutes via the paracellular pathway between adjacent cells (49,50). In the 
gut and lungs, this barrier function is also important to prevent systemic contamination 
by microbes and toxins that are present in the external environment. The tight junctions 
between adjacent epithelial cells, as opposed to endothelial cells, form markedly smaller 
pores between the cells (51,52). Thus it is reasonable to assume that epithelial cells are 
more important for barrier function than endothelial cells. Alterations in intestinal 
permeability are thus a marker of the intestinal barrier function. Therefore, monitoring 
of intestinal permeability is important for early recognition of an intestine at risk, and 
for comparing permeability alterations to other markers of intestinal dysfunction.  
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4.5 Cellular dysfunction
Ischemia and reperfusion of the gut is a multifactorial process that leads to organ 
damage and dysfunction. Interruption of blood supply decreases oxygen and nutrient 
delivery, followed by cellular ionic imbalance, mitochondrial alterations and calcium 
overload. This results in an ischemic injury which rapidly damages tissues with high 
metabolic activity.  
In all species, including humans, a reduction of blood flow to the small intestine, for 
even a relatively short time results in the formation of characteristic mucosal lesions 
(53-55).The enterocytes located at the tips of the villi are particularly susceptible to 
ischemia. This increased sensitivity is thought to be due to the location which is at the 
end of the central arteriole, and thus lower oxygen tension compared to the crypts 
(56,57). Plasma skimming (58) and high metabolic activity of the intestinal epithelial 
cells are also contributing factors. Recent studies have demonstrated that the 
vulnerability of an enterocyte is also dependent on its state of differentiation (59).
Paradoxically, restoration of blood flow to a previously ischemic tissue induces 
additional damage (“reperfusion injury”), mediated, in part, by the extra- and 
intracellular formation of reactive oxygen and nitrogen species. It remains a matter of 
debate whether the reperfusion of ischemic intestine induces mainly necrotic or mainly 
apoptotic cell death (60-62). However, these two processes, although quite different in 
their morphological and biochemical aspects, may often coexist in many pathological 
conditions (63). A key difference between the two forms of cell death is that, during 
necrosis, the membrane integrity breaks down, cytosolic and membrane constituents 
being released into the extra cellular space; whereas during apoptosis, cells shrink and 
their nuclei condense, resulting in their encapsulation into well-enclosed apoptotic 
bodies and followed by consumption by macrophages (64).  
4.6 Glycerol as a marker of cellular damage 
Despite their variable composition, all biological membranes are thought to be 
constructed in a common pattern. They all contain a phospholipid bilayer as the basic 
structure, and membrane-bound proteins, such as receptors and transport proteins. There 
are two major classes of phospholipids: phosphoglycerides that contain glycerol, and 
sphingomyeline composed mainly of sphingosine. To maintain homeostasis, there is 
both passive and active transport over the cellular membrane. In every cell a significant 
fraction of available energy is used to maintain the concentration gradients of ions (such 
as Na+, K+ and Ca+) across the plasma membrane.  
ATP production is decreased under ischemic conditions, thus the active transport 
systems for maintenance of the ion gradients are also depressed. This causes an influx 
of Ca+ into the cells, which activates intracellular phospholipases that attack the cell 
membrane, also causing disintegration of the phospholipid bilayer and efflux of fatty 
acids and glycerol. The amounts of glycerol released are thought to be a marker of cell 
membrane disintegration and cellular necrosis (65-75). 
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4.7 Regional monitoring of the gut 
The assessment of systemic hemodynamic parameters alone fails to reflect regional 
oxygen demand and supply mismatch, the microcirculation and increased blood lactate 
levels (76,77). The gastrointestinal tract has been called the “canary” of the body (78), 
because the intestinal mucosa is one of the first organs affected by inadequate 
splanchnic perfusion / oxygenation. Hence intestinal dysfunction markers provide 
relatively early warning signs of impending systemic affection in e.g. shock, aortic 
surgery, small bowel transplantation, cardiopulmonary bypass, strangulated hernias and 
neonatal necrotizing enterocolitis (79,80). 
Consequently, monitoring of perfusion, oxygenation and function of the liver and the 
intestine are important for diagnosis and treatment.  
Different clinically applicable monitoring techniques of the hepato-splancnic region 
exist. Gastro-intestinal tonometry is the most used clinically applicable device for 
monitoring the splanchnic region. Increases in intestinal tissue partial pressure of carbon 
dioxide (PgCO2) can reflect abnormal oxygen supply to the cells (81,82). The value of 
tonometry as a prognostic tool in critically ill patients is good; the CO2 – gap (difference 
between CO2 in the intestinal tissue and in blood) is a marker of mortality in ventilated 
ICU patients (83). But the results obtained from tonometry – guided therapy remain 
controversial (84-88). Another approach for monitoring the microcirculation is to 
measure the tissue partial pressure of CO2 under the tongue by means of sublingual 
capnometry. This method shows promising results; however, the experience is sparse 
and the method still has several limitations (89-92). 
Intestinal permeability is assessed non-invasively by measuring urinary excretion of 
orally administered test substances (93,94). No currently available test of intestinal 
permeability is however ideal. Confounding factors may interfere both pre- and post-
mucosal, apart from the intestinal permeability itself. Also, the methods only give an 
non-dynamic on and off description whether permeability is increased or not. 
Several other devices have also been developed for the measurement of splanchnic 
blood flow and oxygen transport, e.g. Doppler ultrasound flowmetry (95,96), 
endoscopic laser Doppler flowmetry (97), remission spectrophotometry (98,99), CO2 
probes (100) and indocyanid green clearance (101). These methods are mostly used in 
experimental settings and in clinical research, so clinical experience is infrequent. 
Surgical implantation is almost always necessary, the interpretation of results being 
difficult due to the complex blood flow distribution in the splanchnic region. 
As most of these methods rely on blood flow changes, methods taking into account the 
combination of flow-, permeability- and metabolic alterations are needed. Microdialysis 
may be such a tool.    
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5. Aims;
- To evaluate the use of gut luminal microdialysis as a tool for monitoring ischemic 
metabolites like lactate, glycerol and glucose as markers of intestinal dysfunction during 
and after intestinal ischemia.  
- To evaluate whether microdialysis of glycerol and lactate can be used as a method to 
assess different degrees of intestinal damage and recovery during ischemia and 
reperfusion.
- To assess differences in the information obtained from microdialysis catheters placed 
in the peritoneum, the gut wall and the gut lumen. 
- To evaluate the feasibility of intestinal luminal microdialysis as a method for clinical 
monitoring of the intestine in patients.
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6. Methodological considerations 
The details of the procedures have been described in each paper and only general 
comments concerning the different methods will be given. 
6.1 Microdialysis 
The principle behind microdialysis goes back to the 60’s. Methods like push-pull 
cannulas, dialysis sac’s and dialytrodes were used to study tissue biochemistry directly 
in animals (102-104). In 1974, Ungerstedt and Pycock used a set-up they called “hollow 
fibers” in the brain to mimic the function of blood vessels(105). This method has been 
extensively improved into the method of microdialysis, as we know it today (106). The 
method is widely used both experimentally and in clinical practice for monitoring solid 
organs like brain and skin flaps (107-116). A PubMed search in January 2007 on 
“microdialysis” lists in total 11000 publications, of those 1750 on humans. 
The aim of microdialysis is to sample the extracellular compartment / fluid around the 
probe and monitor its chemical composition as a function of time. A microdialysis 
catheter acts in a similar manner to a blood capillary, sampling the interstitial 
environment by a process of diffusion along a concentration gradient towards and away 
from the cannula (figure 2). The principle of dialysis is explained in terms of Fick’s first 
law of diffusion, which describes the passive movement of molecules down a 
concentration gradient.
Figure 2 
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Microdialysis probes consist of two plastic tubes, one inside the other, and an inlet and 
outlet part, through which fluid is pumped in and flows passively out of the probe and 
into the sampling line. The probe is encircled in the end by a tubular semi-permeable 
membrane, which the fluid passes on its way through the catheter (figure 3). The 
direction of the diffusion process is dependent upon the concentration gradient. Thus, 
microdialysis can be used both for collecting a substance in the dialysate as well as 
delivering it into the periprobe fluid.
Figure 3 
The probes have a diameter often less than 1 mm and the membrane length vary 
between 1-30 mm. The membrane properties and the pore size are the crucial factors 
defining the size of the molecules able to diffuse over and equilibrate with the perfusion 
fluid (called perfusate). 
The probes are either implanted during surgery into organs like the brain, heart and 
solid tumors; or easily placed in soft tissue and the skin at the patients bedside, using an 
introducer cannula. During insertion, the surrounding tissue is temporarily affected 
(bleeding, inflammation), so the probe has to be in situ and undergo a wash-out for 
approx 60 min before measurements can start. The catheters can stay in situ for several 
days, samples can being collected continuously, making dynamic monitoring possible.         
Several factors influence the results obtained from microdialysis, like relative recovery: 
the ratio between the true concentration in the tissue/fluid surrounding the dialysis 
membrane, and the concentration measured in the dialysate. The relative recovery of 
endogenous substances and delivery of drugs is dependent upon a number of variables, 
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including temperature, pH, and the weight, shape and charge of the molecules. It is also 
dependent upon the surface area of the dialysis membrane, the flow of the perfusion 
fluid, the speed of diffusion of the substances through the extracellular fluid and the 
properties of the membrane. If the membrane is long enough and the flow slow enough, 
the concentration in the dialysate will be almost the same as in the interstitial fluid, i.e 
relative recovery approaches 100%. Hydrostatic pressure may also affect the results 
dependent upon the placement of the pump by reducing the sample volume if the pump 
is placed lower than the sampling vial (117). 
The microdialysis probes have to be calibrated before drawing conclusions about 
concentrations in the periprobe fluid. There are many different methods for calibration 
in vivo and thus for determination of relative recovery. The method of flow rate 
variation, when plotting the flow rate against measured concentrations and extrapolating 
to zero flow, will estimate the concentration at zero flow rate (and thus the relative 
recovery) of the probe (118). The no-net-flux method (also called zero-net-flux method) 
is a calibration method making use of different perfusate concentrations (119). The 
calibration method we, and most others, use is in vitro calibration with different known 
concentrations of the marker in the fluid surrounding the probe. However, it is not 
possible to derive in vivo recovery from in vitro results. In general, the relative recovery 
in vitro is higher than in vivo (120) because the relative recovery in vivo depends on the 
additional factors described above. So when interpreting results from microdialysis 
based on in vitro calibration it is important to remember that the only possibility to 
directly use in vitro results is its use for semiquantitative experiments, as it is possible to 
detect changes in analyte concentrations in the tissue surrounding the probe (121). Thus 
we cannot directly compare absolute concentrations of lactate obtained from 
microdialysis perfusate nor from blood samples measured on a blood gas analyzer.  
In all experiments we used CMA 70 Microdialysis Catheters with an outer diameter of 
0.6 mm, and membrane cut-off of 20 kD. To place the luminal catheter, we made a 
small antimesenteric incision and introduced the catheter 10 cm into the lumen. In the 
mucosal approach, a 27-gauge spinal needle punctured the intestinal wall from the 
serosal side, and was guided under visual control and gentle compression against the gut 
wall 5 cm into and out of the mucosa. This thin needle was used as a guidewire for an 
18-gauge needle, in which the catheter was advanced. The needle was then withdrawn, 
and the semipermeable part of the catheter left in situ in the mucosal wall.  
Intraperitoneal catheters were attached to the serosa by a suture. In Paper IV, we 
manufactured our own rectal catheter by combining two commercially available 
devices: a microdialysis catheter (CMA 62) and a 16F tonometric catheter  for 
measurements of regional CO2 production in the intestinal wall. To ascertain contact 
between the catheter and the intestinal mucosa, the microdialysis catheter was attached 
to the tonometry catheter with tape, so that the membrane was at the level of the 
tonometric balloon (fig 4).
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Figure 4. Rectal device 
Schematic drawing of the combined rectal device with microdialysis- and tonometry-
catheter
Rectum
Tonometry catheter
Microdialysis catheter
Microdialysis membrane
6.2 Biochemical analysis 
A CMA 600 microdialysis analyzer was used in all studies to analyze the microdialysis 
samples for glucose, lactate, pyruvate and glycerol. The analyzer is placed at“bedside”, 
the results being available 5 minutes after insertion of the samples. The analyzer is 
based on enzymatic reagents and colorimetric measurements. Analyte specific reagents 
mix with the microdialysis sample and cause formation of hydrogen peroxide if the 
substrate is present. The hydrogen peroxide reacts with a chromogen, catalyzed by 
peroxidase, forming a red-violet quinineomine. The rate of formation of quinineomine 
is proportional to the substrate formation. This reaction is measured photometrically as 
a change of absorbance at 546 nm wavelength during 30 seconds. 
6.3 Measurement of intestinal epithelial permeability 
There are two main approaches to measure intestinal epithelial permeability in vivo. A 
hydrophilic permeability probe (like mannitol or sugars) is administered into the 
intestinal lumen, and the subsequent recovery of the molecule in urine (122) or plasma 
(123,124) is monitored. Alternatively, the experimental animal is infused intravenously 
with an appropriate hydrophilic probe, while the lumen of an isolated segment of 
intestine is perfused with a buffer solution. With this method, permeability is assessed 
by monitoring the plasma-to-lumen clearance of the marker substance (125,126).   
We used venous blood levels and urinary excretion of 14C polyethylene glycol with a 
molecule weight of 4000 Dalton (PEG-4000) as an index for paracellular permeability 
of this probe across the intestinal wall. Hydrophilic probes of this size are considered 
largely to be transported via the paracellular pathway (127,128). They are also approx. 
the size of endotoxins. Because radioactivity of the solution instilled into the intestinal 
loop showed some variations between batches, the blood and urinary levels of PEG-
4000 were expressed as a percent of the amount PEG-4000 instilled into the intestinal 
loop (129). The interpretation of the results from the permeability tests may in general 
be confounded by intestinal transit time and distribution of the probe in various 
compartments other than blood (130). The intestinal transit time was not a problem in 
our model, as the PEG-4000 was introduced into a segment of the intestine ligated in 
both ends. The probe should not be metabolized or degraded in vivo and should be 
cleared only by urinary excretion. PEG 4000 meets both of these requirements. Changes 
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in the glomerular filtration rate might alter the rate of urinary excretion of the probe. To 
diminish this factor, the diuresis was kept normal and the renal blood flow was 
unaffected in both paper II and III. There was also a very similar pattern in blood and 
urine levels supporting this assumption. In paper I, the renal blood flow was reduced 
due to the experimental model.  We therefore are cautious about interpretations of the 
dynamics in the permeability alterations, and only conclude that the permeability was 
increased during reperfusion in that study. 
6.4 Tonometry 
Gastrointestinal tonometry is based on the principle of luminal fluid pCO2 coming into 
equilibration with the pCO2 of the mucosal layer (131) as CO2 diffuses freely in tissue. 
CO2 levels rise sharply in conditions associated with poor tissue perfusion, in part due 
to intracellular buffering of excess hydrogen ions by bicarbonate. The interpretation of 
tissue pCO2 is determined by three variables: the arterial CO2 content, regional blood 
flow, and tissue CO2 production. In stable respiratory conditions, when arterial CO2 is 
constant, tissue CO2 essentially reflects the balance between tissue blood flow and local 
CO2 production. The increased tissue CO2 which occurs in critically ill patients is likely 
to be mainly due to flow stagnation with smaller components brought about by 
anaerobic CO2 production (due to decreased oxygen delivery and cytopathic hypoxia).
There are several pitfalls in interpretation of tonometry-derived results. By using air 
tonometry and measuring the actual tissue CO2 we avoided complex logarithmic 
calculations and dependency of the patient’s acid-base status seen when saline 
tonometry is applied. We measured in the intestine, thereby avoiding the potential errors 
from gastric juice and pancreatic bicarbonate. The experience from tonometry in the 
rectal lumen, as in paper IV, was a challenge, the experience being sparse (132-134). No 
normal value for rectal CO2 has yet been established. Faeces in the rectum surrounding 
the tonometer may disturb the measurements, both due to mechanic obstruction, and by 
CO2 production from faecal bacterias as seen in mice (135). During “dysthermia” 
temperature correction of arterial CO2 is important (136,137).   
6.5 High energy phosphates 
Because oxygen is necessary for mitochondrial generation of adenosine triphosphate 
(ATP), hypoxia will lead to the degradation of ATP. The depletion and, eventually, 
recovery of ATP reflects the ATP-synthesizing capacity of the mithochondria and has 
been recognized as a useful indicator to assess tissue viability in ischemia-reperfusion 
(138). Other data also support the idea that ATP content is a determinant of intestinal 
epithelial barrier function in vivo (139). Tissue samples from the jejunal loops were 
freeze-clamped and immediately frozen in liquid nitrogen, thereafter freeze-dried, 
homogenized, and analyzed for ATP by a standard high performance liquid 
chromatography method (140) (paper II). The technique was developed in the 1960’s 
(141). HPLC separates compounds dissolved in solutions. A small amount of this liquid 
sample is injected into a moving stream of liquid (the mobile phase) that passes through 
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a column packed with particles of stationary phase. Separation of mixture into its 
components depends on different degrees of retention of each component in the column. 
The extent to which a component is retained in the column is determined by its 
partitioning between the liquid mobile phase and the stationary phase. 
6.6 Histology 
Morphology of the intestinal mucosa was evaluated and classified according to Lacy 
and Ito (142). This classification was further modified for the small intestine as reported 
in a detailed study from our laboratory (143).  
6.7 Blood flow determination 
Regional tissue blood flow in the pigs in paper I-III was determined by the colour 
labelled microsphere distribution technique (144). This method is based upon the 
assumption that the amount of embolized microspheres in a tissue mass is proportional 
to the blood flow in that tissue during injection of the microspheres in the left cardiac 
ventricle (145,146). The same principle was also used for determining cardiac output, 
using a reference sample as the “tissue” of interest (147). Tissue blood flow rate and 
cardiac output were calculated as previously described (146,148). The known pit-falls 
of this method (149) were attempted to be avoided by preventing aggregation of spheres 
and using sufficiently high numbers of spheres at each injection. These precautions 
yielded equal distribution of spheres in the right and left kidney as a control of the 
method. Ultrasound transit time flow probes for blood flow measurements were placed 
around the superior mesenteric artery (II-III) and portal vein (I-II) for continuous blood 
flow measurements. 
6.8 Study models 
Young pigs have been used in experimental circulatory research models for many years. 
They have much in common with man in terms of anatomy, physiology and 
metabolism. The pig may be a good model for intestinal ischemia reperfusion in 
humans, because both species have relatively low levels of intestinal xantine oxidase 
(150,151). Therefore, reperfusion injury and the no-reflow phenomenon may be less 
pronounced in pigs and humans compared to rodents and cats.
Surgery and anaesthesia often induce cardiopulmonary depression, alterations in fluid 
balance and regional blood flow, Thus they interfere with the results of an investigation. 
The surgical procedures were done as gently as possible, normovolaemia and normoxia 
being aimed at to counteract these factors influence on the results. The anaesthetic 
combination of fentanyl, midazolam and isoflurane was chosen due to its hemodynamic 
stability, having unaltered splanchnic tissue blood flow over time (152). The same 
maintenance of splanchnic blood flow has also been seen when only using isoflurane 
(153). Isoflurane is a preconditioning agent in the heart (154) and, theoretically, also in 
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the intestine. However, this effect on the intestine has not been shown. In order to 
explore the experimental feasibility of luminal microdialysis, we started with the 
clinically relevant model of aortic cross clamping. However, this model induces a lot of 
“noise”, so in paper II and III we used cross clamping of the superior mesenteric artery. 
The latter model is less influenced by systemic alterations and makes it possible to 
study more isolated effects from controlled intestinal occlusive ischemia.  
The feasibility study on humans (paper IV) was performed on heart surgery patients 
because of the “SIRS-like” behaviour induced by the CPB-circuit, homogeneity as 
patient population, as well as the relatively high risk of gastrointestinal complications.
6.9 Statistics 
In paper I and II, we used parametric tests with two-way ANOVA for repeated 
measurements for testing of differences between the groups. The advantage of this 
approach is the power to identify differences when comparing both within and between 
groups, when the assumptions of residual normality and constant variance is fulfilled. 
When inspecting the data, it is however somewhat debatable whether constant variance 
requirement is fulfilled. Thus, during the revision of paper II, we discussed 
improvements with both the reviewers and statisticians. In the two last papers, we 
recognised and allowed for the non-constant variance along the time line, and turned to 
non parametric tests which include both one-and two-way ANOVA for ranks. Also in 
paper II, we tested all calculations by non parametric tests before publication of the 
paper. The major results in all papers are very clear and hardly influence the 
interpretation of the data regardless of statistical method. 
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7. Summary of results
7.1 paper I
Gut barrier dysfunction as detected by intestinal luminal microdialysis  
In this clinically relevant model of thoracic aortic cross clamping the aim was to 
evaluate the use of gut luminal microdialysis as a tool for monitoring ischaemic 
metabolites as markers of intestinal dysfunction during and after intestinal ischaemia. 
The thoracic aorta was cross clamped for sixty minutes, followed by two hours of 
reperfusion. Glycerol, lactate and glucose in the intestinal lumen and mucosa were 
measured by microdialysis. The recovery of PEG-4000 in blood was used as an index 
for permeability of this probe across the intestinal wall.  
During reperfusion, venous PEG-4000 was increased, remaining unchanged to the end 
of the experiment. During ischemia and reperfusion, there was a marked increase in 
lactate and glycerol in both the intestinal mucosa and lumen. The concentration of 
intestinal luminal and mucosal glycerol concentrations were closely correlated. There 
also seemed to be a correlation between luminal lactate and permeability.  
7.2 paper II 
Gut luminal microdialysis of glycerol as a marker of intestinal ischemic injury and 
recovery
The objective of this study on the one hand, was to evaluate microdialysis as a method 
to assess different degrees of intestinal damage and recovery during ischemia and 
reperfusion, and on the other hand to evaluate information obtained from microdialysis 
catheters placed in the peritoneum, the gut wall and the gut lumen.  
The superior mesenteric artery was cross-clamped for 60 or 120 min, followed by 4 hrs 
of reperfusion. Intestinal mucosal integrity was assessed by morphometry, ATP in the 
gut wall, and permeability of 14C-Polyethylene glycol. Lactate, glycerol, pyruvate and 
glucose were measured by microdialysis in the gut lumen, gut mucosa, the peritoneum 
and in blood.
The histological changes were more pronounced, and the restitution slower after 120 
min compared to 60 min of ischemia; but the permeability alterations were not 
significantly different. Glycerol in the gut lumen closely mirrored the histological 
findings, with a significantly positive correlation between the average amounts of 
denuded basement membrane and gut luminal concentration of glycerol. There was also 
a close correlation between the duration of ischemia and glycerol detected both in the 
gut wall, lumen and peritoneum. Microdialysis catheters placed in the peritoneum did 
not reflect differences between the groups during reperfusion, so when possible the gut 
lumen is to be preferred as a site for placement of microdialysis catheters. 
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7.3 paper III 
Gut luminal lactate levels measured by microdialysis reflects intestinal 
permeability alterations in repeated intestinal ischemia. 
The aim of this study was to investigate the influence of a prolonged initial intestinal 
ischemic insult on transmucosal permeability after a subsequent ischemic event. Based 
on study I and II, we also wanted to further investigate whether microdialysis of 
biomarkers released to the gut lumen is able to reflect changes in intestinal permeability. 
The superior mesenteric artery was cross-clamped for 60 min followed by 4 hrs of 
reperfusion. Intestinal mucosal integrity was assessed by: (1) permeability of 14C-
Polyethylene glycol over the gut mucosa, (2) luminal microdialysis of lactate, glucose 
and glycerol, and (3) tonometry. We demonstrate that a prolonged ischemic insult of the 
intestine confers protection, since mucosal permeability was less increased in response 
to the second ischemic insult as compared to the first. Gut luminal intestinal 
microdialysis of biomarkers, but not tonometry, closely reflects such permeability 
changes. Lactate reflects permeability across the intestinal mucosa more precisely than 
glycerol.
7.4 paper IV 
Endoluminal microdialysis shows increased rectal lactate in routine coronary 
surgery
The aim of the prospective clinical study was to go from the bench to bedside and 
evaluate the feasibility of intestinal luminal microdialysis as a method for clinical 
monitoring the intestine in patients.   
A microdialysis catheter for continuous lactate, glycerol, glucose and pyruvate 
measurements attached to a tonometric catheter was introduced into the lumen of the 
recto-sigmoid junction, and intramuscularly, before surgery in 13 patients undergoing 
elective coronary artery bypass surgery with cardio pulmonary bypass (CPB). The 
patients were followed for 16 hrs postoperatively, and then the rectal catheter was 
removed.   
All patients made an uneventful perioperative course without complications.  Insertion 
of the rectal catheters was uncomplicated, and all but one functioned properly during the 
investigation. After 30 min of CPB, luminal lactate had increased five fold, and 
increased further until the end of CPB. After CPB, gut luminal lactate gradually 
decreased, but still remained elevated above baseline levels at 16 hrs after surgery. 
Intramuscular lactate nearly doubled during CPB, but the lactate pyruvate ratio 
remained unchanged. The intestinal – arterial pCO2 gap was unchanged. Neither 
glycerol nor glucose was detected in the gut lumen.
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8. General discussion 
8.1 Intestinal lactate 
In the splanchnic region, the net production of lactate increases when blood flow falls to 
60-70 % below normal levels (155,156). Even severe intestinal hypoperfusion may be 
present without systemic signs of inadequate blood flow, such as hyperlactatemia. This 
is due to the great lactate clearance capacity of the liver, provided that liver blood flow 
is maintained (157). In sepsis the splanchnic blood flow is often maintained, but still 
lactate is produced in excess in the splanchnic bed (158). The pathophysiology of 
hyperlactataemia is more complex and can involve not only hypoxia (38), but also 
enhanced glycolysis (159), inhibition of pyruvate dehydrogenase (160,161), and 
inhibition of mitochondrial respiration (24). 
Mesenteric venous lactate measurement might be valuable in detecting anaerobic 
metabolism of the gut, but for obvious reasons it is not clinically possible. 
Redistribution of perfusion within the wall (162-164) may yield various lactate 
production in the different layers of the intestinal wall. Therefore, the lactate gradient 
over the mesenteric vascular bed may not represent the metabolic state of the epithelial 
cells, but rather a mixture from all the layers. Thus monitoring of the intestinal mucosa 
is possibly best done from the inside of the intestinal lumen, as first done by Tenhunen 
JJ et al in 1999 (165).
Occlusion of the aorta and superior mesenteric artery as described in Papers I-III caused 
increased lactate within 30 minutes in the gut lumen, mucosa and peritoneum. Lactate at 
these sites was roughly the same at the end of cross clamping of the aorta and the SMA 
for 60 min, as reported by others (166), but did not increase further after 120 minutes of 
occlusion of the SMA. The latter is in accordance to a similar study where Qsma was 
reduced stepwise down to approx. 10% of baseline levels. This induced an increase in 
the mesenteric venous-arterial lactate gradient. This gradient remained high during 
60 min of sustained low Qsma, but did not increase further (157).  The response in lactate 
levels, e.g. no further increase in lactate after 60 minutes of ischemia, despite further 
ongoing ischemia as seen when comparing 60 and 120 min of SMA occlusion (Paper 
II), has also been observed by others (166,168). Neither was ATP further depleted nor 
lactate pyruvate ratio (LP-ratio) further increased in the gut wall from 60 to 120 min of 
ischemia. ATP is produced mainly from oxidative phosphorylation under aerobic 
conditions, and during low flow ischemia from glycolysis (168). There is probably a 
steady state in the lactate production as reflected in our findings. Thus, it is reasonable 
to believe that in these experimental studies the gut luminal lactate represents anaerobic 
metabolism.  
When the blood flow returns to ischemic tissue, the metabolism turns aerobic, and 
lactate levels decline. During reperfusion, gut luminal lactate further increased for the 
first 30 min of reperfusion in our animal experiments. In the gut lumen of patients, and 
mucosa and peritoneum of the pigs, lactate started to decrease immediately after the end 
of the ischemic period, continuing towards baseline. In pigs, baseline was reached in the 
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peritoneum after 1 hr, in the gut wall after 4 hrs (Paper II) and in the gut lumen after 
about 6 hrs (Paper III). In humans (Paper IV), gut luminal lactate had not reached 
baseline levels 16 hrs after the end of operation, however, a substantial decline was seen 
within 6 hours. The response is different in those three compartments. In the 
peritoneum, lactate is probably derived from the underlying muscularis layer via 
diffusion. Lactate during reperfusion with normal blood flow may probably reflect 
systemic levels due to washout. Also, in the gut wall, the lactate levels most likely are 
flow dependent and influenced by the systemic levels and washout. This may explain 
why lactate measurement in the intestinal wall and peritoneum was not able to 
differentiate between the various degrees of damage of the intestinal epithelium in 
response to different duration of cross clamping of the SMA.   
Hyperpermeability is a hallmark of intestinal dysfunction; therefore, monitoring such 
alterations is of great importance. The intestinal surface epithelium is particularly 
susceptible to ischemic damage, being an important barrier between the gut lumen and 
the interstitium and blood. All bio-markers assessed in the present studies have to cross 
this barrier. Under normal conditions without ischemia, it has been shown that blood 
lactate levels must be very high to cause spill over to the gut lumen (165). 
In all of the experimental studies there was a correlation between permeability changes 
across the intestinal mucosa, as assessed by plasma levels of PEG 4000 and release of 
lactate into the gut lumen as measured by microdialysis. In Paper I, figure 3 this 
correlation was pronounced in the early reperfusion period.
Figure 3 from Paper I 
Fig. 3 Relationship between intestinal permeability and lactate detected in the intestinal lumen in seven 
pigs subjected to 60 min of aortic cross-clamping. Abscissa is the relative change in 14C polyethylene 
glycol expressed in percentage during the first 30 min of reperfusion. Ordinate is the corresponding 
concentrations of luminal lactate. p=0.001, y=0.02x +1.53 
In Paper II (fig 1A and 2C) the peak response and the separation of the curves for 
animals with 60 and 120 min intestinal ischemia were essentially the same for changes 
in venous PEG 4000 and gut luminal lactate in response to time. Such a correlation was 
not evident between permeability and changes of lactate in the gut wall and peritoneum.  
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Fig 1A and 2C from paper II
Figure 1A Concentration of PEG-4000 in venous blood as an index of permeability across the intestinal 
mucosa in pigs exposed to 60 (closed squares, n=14) or 120 min (open circles, n=10) of cross-clamping 
of the superior mesenteric artery. On the abscissa 0 denotes baseline, whereas Isch and 30-240 denotes 
time points at the end of the ischemic period and minutes of reperfusion, respectively.  
Figure 2C. Gut luminal levels of lactate detected by microdialysis in pigs subjected to cross-clamping of 
the superior mesenteric artery for 60 min (closed squares) or 120 min (open circles), followed by 
reperfusion for 240 min. On the abscissa, -30 and 0 denotes baseline, whereas Isch and 30-240 denotes 
time points at the end of the ischemic period and minutes of reperfusion, respectively. Values are 
presented as mean (SEM).  
These observations were confirmed and extended in Paper III. The gut luminal lactate 
and venous PEG 4000 qualitatively showed the same response to two subsequent 
ischemic challenges of the intestine (Fig 1A and fig 2A, Paper III). Also, the kinetics 
during the reperfusion was very similar.  
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Figure 1A and 2A from paper III 
Figure 1A. Permeability across the intestinal mucosa . Mean concentrations of PEG-4000 in venous 
blood as an index of permeability across the intestinal mucosa in pigs subjected to cross-clamping of the 
superior mesenteric artery (SMA) for 60 min twice (double clamp group, closed squares) or once (single 
clamp group, open circles), followed by reperfusion. The shaded areas represent cross-clamping of the 
SMA.
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Figure 2A. Gut luminal concentrations of lactate and glycerol 
Mean intestinal luminal concentrations of lactate detected by microdialysis in pigs subjected to cross-
clamping of the superior mesenteric artery (SMA) for 60 min twice (double clamp group, closed squares) 
or once (single clamp group, open circles), followed by reperfusion. On the abscissa, 0 denotes baseline, 
whereas the shaded areas represents cross-clamping of the SMA.  
The small figure depicts the same graph as in the main figures, but with logarithmic scales on the ordinate 
in order to illustrate the degree of log-linear elimination. 
A major conclusion is, therefore, that lactate as measured by microdialysis in the gut 
lumen reflects permeability changes across the gut mucosa. This is of importance 
because it is known that, for example, septic states and CPB may be associated with 
increased intestinal permeability. 
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8.2 Glycerol 
Glycerol as measured with MD has been reported to be a marker of cellular degradation 
in the brain (65-68), liver (72,73), peritoneum (74-75), heart (169) and muscle / 
subcutaneous tissue (69-71).
Cross clamping of both the aorta and the SMA caused increased levels of glycerol in the 
mucosa (Paper I and II), the gut lumen (Paper I-III) and peritoneum (Paper II) within 30 
minutes of ischemia. The concentration further increased depending on the duration of 
the cross clamping. The reproducibility seems fairly good, with almost the same values 
in all three papers (same catheters, almost same recovery). The concentration of 
glycerol differed between the localisations at which it was measured, highest in the 
lumen and substantially lower in the peritoneum. This is most likely explained by the 
intestinal epithelium being more susceptible to ischemic damage (56-58) than other cell 
types in the intestinal wall and abdominal cavity. 
These observations are in agreement with a few other experimental studies which have 
documented a good correlation between intestinal ischemia and increased glycerol in 
the gut wall (170,171), the gut lumen (171) and in mesenterial veins (172). Results from 
sepsis and hemorrhagic shock studies point in the same direction, however, not so 
clearly, there being both unaltered intravasal levels (172) and increased peritoneal (173) 
and gut wall (174) levels. These studies have mainly focused on the ischemic phase 
alone. The present thesis extends these observations by showing that the glycerol levels 
in the gut wall and lumen also reflect the initial ischemic trauma throughout the 
reperfusion and repair phase. 
In Paper II, we showed that release of glycerol to the gut wall, lumen and the peritoneal 
cavity depends on the duration of ischemia. This is in consistence with findings after 
occlusive ischemia in the gut wall and peritoneal cavity (170, 175), and in response to 
endotoxaemia (174). In paper I, gut wall glycerol decreased during 2 hrs of reperfusion, 
whereas luminal glycerol remained elevated. However, extending the reperfusion time 
to 4 hrs as described in Paper II, revealed that there was less injury of the epithelium 
caused by 60 min than after 120 min of ischemia. This was reflected in improved repair 
of the surface epithelium and a decline in gut luminal release of glycerol. Regression 
analysis established a close correlation between release of glycerol and injury of the 
surface epithelial lining in the reperfusion period. Qualitatively, a similar relation was 
noted between gut luminal glycerol and changes in permeability and content of ATP in 
the intestinal wall during the reperfusion period.
Therefore, another major conclusion in the present thesis is that gut luminal glycerol 
when measured by microdialysis is a marker of both cellular damage and repair after 
ischemia of the small bowel. 
Despite the correlation between cellular damage and glycerol levels, we can not 
completely rule out other additive contributing sources of glycerol under endo- and 
paracrine control; Sympathicus mediated lipolysis may increase glycerol levels in fat 
tissues and in systemic circulation (176). Leakage of glycerol to the gut lumen is 
possible, as the permeability was substantially increased in all three experimental 
studies. However, arterial glycerol was not significantly elevated for longer periods in 
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any of the experimental studies. Neither was there any correlation between arterial and 
luminal glycerol levels in paper III.  
Why didn’t we find glycerol in the rectal lumen in patients undergoing CPB? The 
intestinal affection in CPB is due to SIRS-like reaction (177), somewhat different from 
the occlusion models in paper I-III. Thus, the difference between the gut glycerol 
response to occlusive ischemia and sepsis may be caused by the different mechanisms 
behind the eventual cellular damage. In occlusive ischemia there is probably an 
overweight of necrosis causing cellular disintegration (64) and release of glycerol. In 
sepsis and other SIRS models, such as CPB, the mechanism is probably a overweight of 
apoptosis of the cells in the intestine (178,179) without any washout of cellular content 
to the interstitium and therefore no release of glycerol.  
8.3 Glucose. 
In muscle, extra cellular glucose decreases to approximately 50% of pre-ischemic levels 
during 30 min ischemia, further decreasing to 20% of pre-ischemic levels after 60 min 
ischemia. Both of these decreases are due to cessation of delivery and consumption 
(180).
After both aortic and SMA cross clamping, glucose in the gut wall became virtually 
undetectable, but returned to baseline levels 30 minutes after unclamping (Paper I-II). 
This is in concordance to findings in pigs subjected to stepwise mesenteric blood flow 
reduction. In each step there was a 15% reduction. Here, 30% flow reduction from 
baseline was associated with a decrease in microdialysis glucose concentration of 80 %, 
and is an early sign of anaerobic metabolism (181).  
In the gut lumen, under baseline conditions and during occlusive ischemia, glucose is 
undetectable by microdialysis (171, I-II). Intestinal ischemia has also been demonstrated 
in vitro to abolish the absorption of eventual glucose from the gut lumen (182,183).  
The information about what happens during reperfusion is sparse. We have found that 
after unclamping, glucose becomes detectable in the gut lumen (Paper I-III), and even 
tends to reflect the degree of permeability alterations (Paper III). It is tempting to 
speculate that when the blood flow is restored, glucose passes over the damaged 
intestinal barrier proportionate to the alterations in permeability. After 1 to 2 hrs of 
reperfusion, there is no longer any glucose in the gut lumen; the correlation to the 
cellular restitution is striking, so maybe the glucose absorptive properties is recovered 
(182,183). At least, the appearance of glucose can be used as a sign of recovered 
intestinal blood flow.
8.4 Clinical aspects and future research 
Microdialysis has properties which enable it to be used more extensively in monitoring 
intestinal function, both experimentally and in clinical practice. Microdialysis probes 
placed inside the intestine (gut luminal microdialysis), detect deteriorated metabolism, 
the extent of cellular damage and increased permeability. In contrast to catheters placed 
in the peritoneal cavity, catheters placed in the gut lumen also make it possible to follow 
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the course during reperfusion. In patients, the placement of microdialysis probes, as 
they are manufactured today, is best in the abdominal cavity, due to the relative fragility 
of the microdialysis catheters. However, this is an invasive procedure having possible 
concurrent complications, the patient population being limited to those undergoing 
abdominal surgery.  
Due to the ability of gut luminal microdialysis to monitor functional recovery of the 
intestine, we believe that this is the best approach in patients. The regional blood flow 
heterogeneity in sepsis (184), mesenterial hypoperfusion (181) and during acute 
normovolemic hemodilution (185), cause challenges concerned with what is the best 
part in the intestine in which to place the catheters. The alterations in permeability and 
lactate production in SIRS conditions make the rectal lumen a possible approach. 
Insertion of the catheter is a less invasive method and can be done pre and 
postoperatively. This is also true in critically ill patients in the ICU. The search for other 
possible biomarkers of intestinal dysfunction must be continued.  
The probes have to be reinforced for safer and easier insertion. The optimal way to do it 
is not yet known; only further research may define the place of dialysis bags, large 
rectal dialysis tubes, reinforced combined MD and tonometry catheters or 
biosensors………….
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9. Conclusions 
Lactate, glycerol and glucose are released into the gut lumen in ischemia 
and reperfusion (IR). 
Glycerol is a marker of cellular damage, and is independent of systemic 
levels
Lactate mirrors permeability alterations in the intestine 
Intestinal ischemia can be detected with the microdialysis technique in the 
gut wall, lumen and in the peritoneum. 
The gut lumen is to be preferred as a site for placement of microdialysis 
catheters when monitoring recovery / reperfusion 
Gut luminal microdialysis can differentiate between various degrees of 
intestinal damage. 
Gut luminal microdialysis is a clinically feasible method for monitoring 
intestinal integrity
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Running head: Gut luminal lactate mirrors intestinal permeability
Summary statement: A prolonged initial ischemic insult of the intestine confers 
protection, in terms of reduced hyperpermeability, against further ischemia. 
Microdialysis of biomarkers mirrors permeability changes associated with this type of 
protection. Lactate reflects permeability across the intestinal mucosa more precisely 
than glycerol. 
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ABSTRACT:
Background: The aim of the present study was to investigate the influence of a 
prolonged initial intestinal ischemic insult on transmucosal permeability after a 
subsequent ischemic event, and whether microdialysis of biomarkers released to the 
gut lumen is able to reflect changes in intestinal permeability.  
Methods: The superior mesenteric artery was cross-clamped for 60 min followed by 4 
hrs of reperfusion in 16 pigs. Nine pigs had a second cross-clamp of 60 min, and 3 hrs 
of reperfusion, while 7 were observed for further 4 hrs of reperfusion. Intestinal 
mucosal integrity was assessed by permeability of 14C-polyethylene glycol (PEG-
4000) over the gut mucosa, luminal microdialysis of lactate, glucose and glycerol, and 
tonometry.  
Results: During reperfusion, the PEG-4000 amount in venous blood was two times 
higher after the first than after the second ischemia (AUC: 44780 (13441-82723) vs. 
22298 (12213-49698) counts·min/mL, p=0.026 (mean (range)). There was less lactate 
detected in the gut lumen after the second ischemia compared to the first (AUC: 797 
(412-1700) vs. 1151 (880-1969) mmol·min/L, p=0.02) and a lower maximum 
concentration (4.8 (2.7-9.4) vs. 8.5 (5.0-14.9) mmol/L, p=0.01). The same pattern was 
also seen for luminal glycerol and glucose. During the second ischemia, the intestinal 
mucosal/arterial CO2-gap was identical to the level during the first ischemic episode. 
Conclusions: A prolonged ischemic insult of the intestine confers protection, in terms 
of reduced hyperpermeability, against further ischemia. Microdialysis of biomarkers 
mirrors permeability changes associated with this type of protection. Lactate reflects 
permeability across the intestinal mucosa more precisely than glycerol. 
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INTRODUCTION
Increased intestinal permeability is a key manifestation of intestinal dysfunction 
caused by ischemia/reperfusion of the gut (1-3), and is associated with an increased 
risk of multiple organ failure. (4-9). Ischemic preconditioning (IPC) in various tissues 
including the intestine (10-14) refers to the observation that short periods of ischemia 
(5-15 min) induce protection against tissue injury. However, it is not clear whether a 
more prolonged period of intestinal ischemia, as seen initially in hypovolemic and 
septic shock, may influence changes in intestinal permeability caused by later 
ischemic events. Development of reliable methods for monitoring intestinal barrier 
dysfunction is essential in order to improve the care of patients with conditions 
associated with ischemia reperfusion challenge of the gut.  Microdialysis allows 
monitoring of extracellular substances in gut submucosa and lumen, also in the 
clinical setting (15). We have recently shown that microdialysis of the biomarker 
glycerol released to the gut lumen provide information about tissue injury after 
intestinal ischemia (16), whereas release of lactate to lumen may be a measure of 
permeability (17). 
The aim of the present study was 1) to investigate the influence of a clinically relevant 
initial intestinal ischemic insult on transmucosal permeability after a subsequent 
ischemic event, and 2) to investigate whether tonometry and microdialysis of 
biomarkers released to the gut lumen is able to reflect changes in intestinal 
permeability in this experimental model.  
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MATERIALS AND METHODS
The Norwegian State Commission for Animal Experimentation approved this study. 
All procedures were consistent with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals (NIH publication 85-23, revised 1996). 
Anesthesia and surgical preparation 
The superior mesenteric artery (SMA) was cross-clamped for 60 min followed by 4 
hrs of reperfusion in 16 pigs (bodyweight 19-27 kg). They were then randomized in 
two groups; Nine pigs had a second cross-clamp of 60 min and 3 hrs of reperfusion 
(double clamp group), while 7 were only observed for further 4 hrs of reperfusion 
(single clamp group). After i.m. premedication with diazepam 10 mg (Stesolid, 
Dumex-Alpharma, Copenhangen, Denmark), azaperon 400 mg (Stresnil, Janssen-
Cilag, Wien, Austria) and atropine 1 mg (Atropin, Nycomed Pharma, Oslo, Norway), 
anesthesia was induced with thiopental sodium 5-10 mg/kg (Pentothal-Natrium, 
Abbott Scandinawia AB, Solna, Sweden) and ketamine 10 mg/kg (Ketalar, Parke-
Davis, Solna, Sweden). A tracheotomy was performed and the animals were 
mechanically ventilated with a Servo ventilator 900 B (Siemens –Elema, Sweden). 
FiO2 was kept at 0.3, tidal volume at 10 ml/kg and minute ventilation was adjusted to 
maintain PaCO2 of 34-41 mmHg (4.5 - 5.5 kPa) and kept unchanged during the 
experimental period. Anaesthesia was maintained with isoflurane 0.5% (Forene, 
Abbot Scandinavia AB, Solna, Sweden), and a continuous infusion of fentanyl 7.5 
µg/kg/hour (Fentanyl, Alpharma AS, Oslo, Norway) and midazolam 0.5 mg/kg/hour 
(Dormicum, Roche, Basel, Switzerland). The femoral artery was cannulated for heart 
rate, mean arterial blood pressure, and blood gas measurements (ABL 330 radiometer, 
Copenhagen, Denmark). Another catheter was inserted into the inferior cava vein for 
blood samples. A 4 FG catheter was introduced via the right common carotid artery 
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into the left cardiac ventricle for infusion of coloured microspheres. The animals 
received Ringer acetate at an infusion rate of 10-15 ml/kg/h. A heating blanket and 
warmed fluids were used to maintain a constant core temperature of 38.5 oC. A 
midline laparotomy was performed, and a catheter inserted into the urinary bladder. 
An ultrasonic transit-time flow probe (6 mm) was placed around the SMA for 
continuous blood flow measurements. A vessel loop for cross-clamping was placed 
proximal to the flow probe on the superior mesenteric artery. After surgical 
preparation, the animals were allowed to stabilize for 60 min, thereafter baseline 
measurements were collected for 45 min. 
Regional blood flow 
Intestinal tissue blood flow and cardiac output were determined by the distribution of 
coloured microspheres during baseline, 10 min after the first cross-clamping and 10 
min after the first and second declamping (18). 
Permeability
Intestinal permeability was determined as described previously (19). Briefly, a 30 cm 
length of jejunum was ligated at both ends and 100 ml (10.0 PCi) 14C polyethylene 
glycol (PEG-4000) (Amersham Bioscience, Buckinghamshire, England) was injected 
into the lumen. Venous blood samples for determination of the concentration of PEG-
4000 in plasma were taken at 30 min intervals, and urine samples were taken hourly.
Microdialysis 
A microdialysis catheter (CMA 70, membrane length 20 mm, 20 kD, CMA 
Microdialysis AB, Stockholm, Sweden) was introduced into the jejunal lumen 40 cm 
distal to the ligament of Treitz, as recently reported from our laboratory (17). A 
microdialysis catheter (CMA 70) was also introduced into the subclavian artery. The 
microdialysis catheters were perfused at a flow rate of 1 µL/min with an isotonic 
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perfusion fluid (CMA Perfusion Fluid T1 (Na+ 147 mmol, K+ 4 mmol, Ca2+ 2.3 
mmol, Cl- 156 mmol per L) and a microdialysis pump (CMA 107, CMA 
Microdialysis AB, Stockholm, Sweden). The catheters were perfused in situ for at 
least 75 minutes before baseline measurements. Samples were collected over 30 
minutes, and were analyzed immediately on site for glycerol, lactate, pyruvate and 
glucose concentrations by enzymatic fluorometric assays (CMA 600 Microdialysis 
analyzer) using peroxidase methodology. In vitro recovery with a flow rate of 
1µL/min was 65 (41-70) % (mean (range)) for lactate, 22 (17-33) % for pyruvate, 36 
(30-44) % for glycerol and 33 (25-43) % for glucose. 
Tonometry
A tonometry catheter (16F, Tonometrics, Datex-Ohmeda, Finland) was introduced 
into the jejunal lumen 60 cm distal to the ligament of Treitz through an 
antimesenterial incision, and calibrated in situ. Gut mucosal PCO2 (PiCO2) was 
measured using an automated air tonometry system (Tonocap, TC-200; Datex-
Ohmeda, Helsinki, Finland). Gut mucosal PiCO2 and arterial blood gas measurements 
(ABL 330 radiometer, Copenhagen, Denmark) were simultaneously measured every 
30 minutes and the difference between PiCO2 and arterial PCO2 (PaCO2),the CO2-gap, 
was calculated at each time point (regional CO2-gap) .
Statistics and calculations
All values are expressed as medians and ranges where not otherwise mentioned.  
For comparisons between the double and single clamp groups at various time points 
we used the Mann-Whitney U test. To assess changes within the groups over time, the 
Friedman test was used. The Wilcoxon signed-rank test was applied for paired 
samples to evaluate differences between specific time points or area under the curves 
(AUC) within the groups. Linear regression was performed to investigate and plot the 
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association between arterial and luminal values within each pig for specific time 
intervals. SPSS for windows version 13, (SPSS Inc, Chicago Illinois, USA) was used 
for the statistical analyses. 
Formation and elimination kinetics of lactate, glycerol and PEG-4000 were calculated 
as follows: Maximum concentrations (Cmax) and the times to achieve maximum serum 
concentrations (tmax), were obtained directly form the measured values. Other 
parameters were calculated by means of the Kinetica program package, version 4.3 
(InnaPhase Corporation, Philadelphia, PA, USA), using a non-compartment model. 
Areas under the curve from the start of the first and of second clamping, respectively, 
to 240 minutes later (AUC0-240) were calculated using the trapeziodal rule. The 
parameter estimates describing the elimination phase of the log-concentrations (Oz)
were calculated using the best-fit regression lines, taking the degree of log-linearity 
into account. The elimination half-lives (t½) were calculated as ln2/Oz.
Before start of the second cross-clamping, baseline levels of lactate and glycerol were 
significantly higher than before the first cross-clamping. To improve the 
comparability between the first and the second clamps we subtracted mean values at 
the corresponding time points from the single clamp group during the last episode of 
ischemia and reperfusion. 
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RESULTS
There were no significant differences in the measured parameters at baseline between 
the groups, except for heart rate (Table 1). All animals survived throughout the 
experiment. 
Hemodynamic variables
The hemodynamic variables during the experiment are presented in Table 1. Mean 
arterial pressure was elevated from baseline only during cross-clamping in both 
groups. Heart rate increased during the first clamp in both groups, and remained 
elevated for the rest of the experiment. Cardiac output did not change during the 
experiment. The blood flow of the SMA was zero during cross-clamping and returned 
to baseline during reperfusion.  
Blood flow measured both in the whole jejunal wall and in the serosa fell to zero 
during cross-clamping of the SMA, and returned to baseline levels during reperfusion 
after both ischemic episodes. Jejunal mucosal blood flow also fell to zero after 
clamping of the SMA. After the first ischemic episode, blood flow returned to 
baseline, whereas after the second ischemic episode, blood flow was higher than 
baseline, p=0.027. 
Intestinal permeability  
PEG-4000 at baseline and during the first clamping was not detectable in venous 
blood or urine. During reperfusion, the mean AUC0-240 of PEG-4000 in venous blood 
was two times higher after the first than after the second ischemia, (44780 (13441-
82723) vs. 22298 (12213-49698) counts·min/mL, p=0.026) (Figure 1A). The same 
pattern was seen for Cmax (mean 394 (117-632) vs. 140(105-330) counts/ml, p=0.035). 
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The PEG-4000 levels declined log-linearly during both the first and second 
reperfusion with mean elimination half-lives of 133 (67-224) and 117 (76-149) min, 
respectively (p=0.434). The excretion of PEG-4000 in urine largely mirrored the 
venous concentration of this marker molecule, although the peak excretion after 
declamping of the SMA occurred about 1 hour later than the peak concentration of 
venous PEG-4000 (Fig 1B). 
Intestinal lumen 
Lactate. The response to the first cross-clamping of the SMA was similar in both 
groups with increased lactate levels within 30 min (p<0.05) (Figure 2A). The mean 
Cmax was 8.5 (5.0-14.9) and 7.8 (5.8-11.5) mmol/L in the first clamp in the double 
clamp group and single clamp groups, respectively, (p=0.408), and was reached after 
a median of 30 (0-180) min of reperfusion. The lactate levels declined log-linearly 
during reperfusion with a mean elimination half-life of 90 (26-165) min (small figure 
in figure 2A), and baseline levels were reached in the single clamp group after 390 
min of reperfusion. The response to the second cross-clamping was less pronounced 
compared to the first occlusion, with a mean AUC0-240 of 797 (412-1700) vs. 1151 
(880-1969) mmol·min/L, p=0.02 and a mean Cmax of 4.8 (2.7-9.4) vs. 8.5 (5.0-14.9) 
mmol/L, p=0.01.
Glycerol. The first cross-clamp of the SMA caused an increase in gut luminal glycerol 
in both groups after 30 min (p=0.04) (Figure 2B). Mean Cmax for glycerol was similar 
in the double clamp and the single clamp groups (971 (735-1538) vs. 826 (619-1351) 
µmol/L, p=0.142), and was reached after mean of  90 (30-180) min of reperfusion. 
The glycerol levels declined in a non-log-linear way during reperfusion (small figure 
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in Figure 2B), and baseline levels were reached in the early clamp group after 360 
min of reperfusion.  
The response to the second clamp differed from the first. Mean Cmax of luminal 
glycerol was higher in the first clamp than in the second (971 (735-1538) vs. 404 (49-
1195) µmol/L, p= 0.02). There was also a trend toward the same regarding AUC 
(131214 (71253-215517) vs. 45281 (1581-213489) µmol·min/L, p=0.07). The tmax
values were the same in first and second clamp (median 150 (90-210) vs. 120 (30-
210) min, p=0.174).   
Glucose in the gut lumen was only detected during reperfusion, and the mean AUC 
was higher during the first than during the second clamp (43 (0-197) vs. 3 (0-28) 
mmol·min/L, respectively, p=0.008). 
Regional CO2-gap.
The regional CO2-gap increased 4-fold during the first occlusion in both groups 
(p=0.008) (Figure 3), but returned to baseline levels after 240 min of reperfusion. 
During the second ischemia, the values both for the increase in and the maximal level 
of the CO2-gap were identical to the corresponding values during the first ischemic 
episode.
Arterial blood 
Arterial blood concentrations of glucose, lactate, pyruvate and glycerol are presented 
in Table 2. The arterial lactate concentration was only significantly higher than 
baseline at 60 min of every cross-clamp(p=0.012). In Figure 4 A, individual arterial 
lactate concentrations in the double clamp group are plotted against corresponding 
luminal lactate concentrations during baseline and both reperfusion periods. In linear 
regression analyses accounting for the intra- and interindividual variance of the pigs, 
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we found an association between arterial and luminal lactate levels, which was most 
pronounced in the first reperfusion (p<0.01).
The arterial pyruvate concentration was only significantly increased after 60 minutes 
of the first ischemia (p=0.039), and decreased below baseline levels after 240 min of 
reperfusion in the single clamp group (p=0.016). Arterial lactate-pyruvate ratio was 
not elevated from baseline levels. The arterial glycerol concentration was only 
increased above baseline at one single time during the first clamping period 
(p=0.027). The arterial glycerol concentrations are also plotted against luminal 
glycerol concentrations at the same three time intervals (Figure 4B) as with lactate, 
but we found no significant associations between arterial and luminal glycerol levels.
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DISCUSSION 
In this study with two ischemic episodes, we demonstrate that mucosal permeability 
was less increased in response to the second ischemic insult. Gut luminal intestinal 
microdialysis of biomarkers, but not tonometry, closely reflect such permeability 
changes.
The improved mucosal barrier function after the second ischemic insult is consistent 
with the only published study that clearly has demonstrated an effect of 
preconditioning (3 cycles of 2 min ischemia/5 min reperfusion) on transmucosal 
permeability in response to a subsequent challenge by ischemia (14). The current 
study extends these observations by showing that even a 60 min ischemic event in the 
gut, comparable to what may be encountered before effective resuscitation after 
hypovolemic and septic shock, may elicit defence mechanisms like those responsible 
for the preconditioning phenomenon. It was beyond the scope of the present study to 
further characterize these mechanisms, but certain features of the experimental model 
deserve comments. We have found in a recent study that that there is no worsened 
injury of the mucosa, as judged by microscopy, throughout the reperfusion period 
after ischemia (16).Both in that study and in the present, hyperpermeability across the 
mucosa after ischemia was not sustained or increased, but instead decreased 
throughout the reperfusion period. Mucosal blood flow was rapidly restored to normal 
levels after the ischemic period, indicating absence of the no-reflow phenomenon (i.e. 
full return of nutritive perfusion after ischemia) in this layer of the intestinal wall (20). 
These features are in contrast to findings during reperfusion, particularly in rodent 
models of ischemia/reperfusion injury of the gut, in which progressive structural and 
functional derangements of the mucosa and the no-reflow phenomenon are hallmarks 
of events caused by activation of reactive oxygen species (21). We therefore suggest 
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that the reperfusion injury in the porcine intestine is blunted as compared to many 
other commonly used ischemia/reperfusion models. It is possible that adaptive 
protective mechanisms are particularly up regulated in response to reperfusion in the 
porcine intestine, which may be one underlying reason for the improved barrier 
function after the second ischemic insult in the current study. 
Qualitatively, concentrations of lactate, glucose and glycerol in the intestinal lumen, 
mirrored the attenuated hyperpermeability after the second ischemic insult (Figures 
1and 2). However, the time course with regard to increase and elimination from the 
gut lumen indicates certain differences between lactate and glycerol. As shown in 
Figures 1 and 2, the maximum level of lactate and PEG-4000 occurred at exactly the 
same time and, importantly, the slope of the elimination curve was almost identical. In 
contrast, the luminal decrease of glycerol was much slower (Figure 2). This suggests 
that lactate is a more precise measure of permeability than glycerol. A likely 
explanation for these observations may be sought by the origin of lactate and glycerol 
released to the gut lumen in response to ischemia. It is known that the surface 
epithelium of the gut is much more susceptible to ischemia than cells in the deeper 
part of the gut wall (22-24), and disintegration of the cell membranes induce release 
of glycerol into the gut lumen (16). There is a close correlation between intestinal 
cellular damage and glycerol levels (16), thus the smaller total amount of glycerol in 
the gut lumen in the second ischemic period probably reflects less destruction of the 
intestinal epithelium and not altered permeability. Lactate released into the lumen is at 
least to a large part produced due to anaerobic metabolism in all cell types of the 
mucosa and muscular layer, not only the epithelium. 
Arterial concentrations of the biomarkers, and particularly lactate, may also influence 
their release into the intestinal lumen. With an intact surface epithelial barrier it has 
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been shown that even high systemic levels of lactate do not influence the gut luminal 
concentration of lactate (25). As shown in Figure 4A there was a correlation between 
systemic and luminal lactate in the reperfusion period coinciding with increased 
permeability. This suggests that systemic lactate may contribute to luminal release of 
lactate. However, considering the gradient between lumen and blood, the local 
production in the intestinal wall is probably the most important source of luminal 
lactate. There was no correlation between systemic and luminal release of glycerol. 
These findings further support the conclusion put forward above that luminal lactate 
better reflect permeability than glycerol. 
The transport of lactate during ischemia is rather complex. Lactate crosses cell 
membranes by interaction with specific proteins; the monocarboxylate transporters, 
which are trans-membrane proteins facilitating cotransport of a monocarboxylate ion 
with a proton (26). Acidosis increases both paracellular and transcellular permeability 
to hydrophilic (macro)molecules such as fluorescein disulfonic acid (FS; molecular 
weight 478 Da, and fluorescein isothiocyanate-labeled dextran (FD4; average 
molecular weight 4 kDa) in human intestinal epithelial Caco-2BBe cells grown as 
monolayers (27). Metabolic acidosis due to ischemia may thus influence on the lactate 
transport from the cells into the intestinal lumen as with larger molecules like PEG-
4000.
On the contrary, CO2 freely diffuses out of cells and into the interstitial fluid. 
Increases in tissue CO2 are primarily a function of changes in regional blood flow, 
independent of the degree of tissue dysoxia (28). This is in accordance with our 
findings with the same blood flow and CO2 alterations in both ischemic episodes. It is 
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therefore not surprising that tonometry failed to reflect permeability changes across 
the mucosa.  
In summary, the present study provides evidence for the conclusion that even a 
prolonged ischemic insult of the intestine confers protection, in terms of reduced 
hyperpermeability, against further ischemia. Microdialysis of biomarkers mirrors the 
permeability changes associated with this type of protection. Lactate reflects 
permeability across the intestinal mucosa more precisely than glycerol. 
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Table 1 Hemodynamic variables 
Measurements Group Baseline 1st clamp 1st reperfusion 2nd clamp 2nd reperfusion p-value
DoMean arterial pressure 
(mmHg) 
uble clamp 69 (61-89) 94 (79-113) 69 (67-75) 84 (81-116) 72 (55-83) 0.020
Single clamp 61 (47-83) 83 (62-111) 74 (51-86) N/A 76 (61-86) 0.001
p-value 0.284 0.134 0.778 0.936
Double clamp 7.0 (3.4-9.6) 6.0 (3.1-11.6) 6.3 (3.3-9.0) N/A 5.3 (2.6-14.9) 0.153Cardiac output (L/min) 
Single clamp 6.9 (4.1-8.5) 5.2 (3.0-6.9) 7.2 (3.9-14.5) N/A 6.9 (6.3-13.2) 0.297
p-value 0.536 0.918 0.470 0.174
Double clamp 80 (65-104)* 101 (66-180) 97 (65-171) 95 (63-178) 124 (93-189)* 0.005Heart rate (beats/min) 
Single clamp 63 (51-81) 92 (55-144) 84 (54-124) N/A 84 (56-188) 0.001
p-value 0.029 0.133 0.606 0.015
Double clamp 28 (15-40) 0 (0) 32 (7-52) 0 (0) 22 (6-41) 0.000QSMA (mL/kg/min) 
Single clamp 21 (19-25) 0 (0) 23 (17-28) N/A 21 (15-26) 0.000
p-value 0.536 0.475 0.408 0.837
Double clamp 0.47 (0.21-0.79) 0.01 (0.00-0.03)* 0.46944 N/A 0.49 (0.16-0.94) 0.000Qjejunal wall (mL/min/g tissue) 
Single clamp 0.44 (0.33-0.68) 0.03 (0.02-0.18) 0.495 N/A 0.63 (0.37-1.17) 0.000
p-value 0.918 0.010 0.606 0.351
Double clamp 0.48 (0.14-0.84) 0.01 (0.00-0.06) 0.49 (0.24-1.40) N/A 0.75 (0.36-1.20) 0.000Qmucosa (mL/min/g tissue) 
Single clamp 0.41 (0.22-0.48) 0.02 (0.01-0.10) 0.45 (0.12-0.83) N/A 0.48 (0.15-0.91) 0.000
p-value 0.606 0.365 0.837 0.210
Double clamp 1.18 (0.05-2.93) 0.01 (0.00-0.04) 0.35 (0.06-0.89) N/A 0.52 (0.12-1.25)* 0.000Qserosa (mL/min/g tissue) 
Single clamp 0.71 (0.29-2.49) 0.03 (0.00-0.23) 0.31 (0.09-2.11) N/A 1.16 (0.43-3.60) 0.000
p-value 0.791 0.096 0.958 0.030
Double clamp 34 (29-53) 36 (24-45) 38 (27-46) 40 (25-47) 42 (28-50) 0.145Arterial PCO2 (torr) 
Single clamp 35 (26-48) 38 (26-55) 43 (27-51) N/A 41 (27-79) 0.086
p-value 0.817 0.778 0.142 0.816
All values are expressed as medians (ranges). QSMA, QJejunal wall QMucosa and QSerosa are blood flow in the 
superior mesenteric artery and intestinal wall (entire wall, mucosa and serosa), respectively. The 
superior mesenteric artery (SMA) was cross-clamped for 60 min twice (double clamp group) or once 
(single clamp group), followed by reperfusion. Cardiac output and intestinal tissue blood flow were 
determined 15 min before the end of the first cross clamping of the SMA and at given time points. 
Other values are medians in each pig during baseline, ischaemia and reperfusion periods, respectively.  
P-values in the right column represent comparisons within groups over time. * P<0.05 compared to the 
single clamp group.  
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Table 2 Arterial concentrations of glucose, lactate, pyruvate and glycerol
Measurements Group Baseline 1st clamp 1st reperfusion 2nd clamp 2nd reperfusion p-value
Double clamp 4.6(1.6-5.5) 5.6(2.3-6.6) 4.5(2.3-4.9) 4.2(1.8-6.1) 3.9(2.3-4.9)  0.001 
Single clamp 5.1(4.6-6.2) 6.5(4.8-8.2) 4.9(4.0-7.3)  N/A 4.50(3.5-6.2) 0.139
Arterial glucose 
concentration, mmol/L 
 p-value  0.071  0.174 0.114  0.115
Double clamp 1.5(0.7-2.2) 1.4(1.0-4.6) 0.8(0.6-6.2) 1.1(0.5-2.8) 0.8(0.5-3.5) 0.000
Single clamp 1.3(0.9-1.9) 1.4(1.2-2.2) 0.8(0.5-2.5)   N/A 0.5(0.3-1.4) 0.000
Arterial lactate concentration, 
mmol/L 
 p-value 0.918 0.918 0.681 0.71
Double clamp 123(70-208) 142(90-299) 98(57-343) 102(75-386) 81(50-223) 0.001
Single clamp 162(102-240) 202(111-423) 135(62-300)   N/A 68(52-111) 0.001
Arterial pyruvate 
concentration, µmol/L 
 p-value 0.299 0.299 0.758 0.336
Double clamp 11(7-15) 11(7-17)* 11(6-18) 9(7-19) 11(7-16)* 0.436
Single clamp 8(5-18) 8(3-12) 8(6-12)   N/A 8(5-11) 0.086
Arterial lactate/pyruvate 
concentration-ratio 
 p-value 0.299 0.016 0.071 0.021
Double clamp 13(0-28) 15(11-126) 10(0-133) 15(0-112) 16(0-76) 0.001
Single clamp 13(0-31) 29(13-128) 14(6-76)   N/A 13(0-64) 0.021
Arterial glycerol 
concentration, µmol/L 
 p-value 0.536 0.408 0.836 0.837
All values are expressed as medians (ranges). The superior mesenteric artery (SMA) was cross-
clamped for 60 min twice (double clamp group) or once (single clamp group), followed by reperfusion. 
Values are medians (range) in each pig during baseline, ischaemia and reperfusion periods, 
respectively. P-values in the right column represent comparisons over time in each group. * P<0.05 
compared to the single clamp group.  
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Figure 3 
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Paper IV 
Paper IV is not included due to copyright. 
 
12. Erratum 
1. In Paper I, page 1189 the dosage of fentanyl must be corrected to 7.5µg/kg, and 
not as written: 75µg/kg. 
2. Paper II, see erratum in Crit Care Med 2007;35:333
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